SEC Tracker
Get the app

Enanta Pharmaceuticals ENTA

The Board of Directors of Enanta Pharmaceuticals, Inc. designated Harry R. Trout, III

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Reports an executive or board change (5.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Enanta Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  2. Milestone Pharmaceuticals MIST public float $99M, Jun 30, 2025
  3. DiaMedica Therapeutics DMAC public float $96M, Jun 30, 2025
  4. Larimar Therapeutics LRMR public float $95M, Jun 30, 2025
  5. GENELUX GNLX public float $89M, Jun 30, 2025